Real-world rates and sites of recurrence after neoadjuvant chemoimmunotherapy in early-stage triple-negative breast cancer
Year: 2026
Type: article
Study design: Observational Study
Abstract: Neoadjuvant chemoimmunotherapy (NAC + P) improves pathologic complete response (pCR) and survival in early-stage triple-negative breast cancer (TNBC) compared to neoadjuvant chemotherapy (NAC) alone. Real-world recurrence outcomes outside the trial setting remain unclear. This single-institution analysis compared two cohorts of patients with early-stage TNBC treated between July 2009 and April 2023: NAC + P ( n = 344) and NAC ( n = 513). Primary outcomes were local (LR), regional (RR), and distant recurrence (DR); secondary outcomes were DR sites and disease-free survival (DFS). The NAC + P cohort presented with less advanced disease at diagnosis. Overall pCR was higher in NAC + P (58% vs. 36%, p < 0.001). Two-year LR and RR rates did not differ. The 2-year DR rate was nearly halved in NAC + P (9.6% vs. 18%, p < 0.001) and remained lower among patients with residual disease (16% vs. 25%). Two-year brain recurrence was also lower (3.5% vs. 6.6%, p = 0.046). Overall pCR was independently associated with improved DFS in both cohorts, as were immune-related adverse events (irAEs) in NAC + P. In this real-world setting, NAC + P was associated with substantially lower 2-year DR, though the central nervous system remained a common site of recurrence. Beyond pathologic response, the development of irAEs may offer a treatment-specific marker of benefit.
Source: npj Breast Cancer
Institution: Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,790
OpenAlex ID: W7236490501
